Gilead Sciences Inc. (GILD)
3 Cash-Flow Machines Investors May Want Heading Into 2026
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how a firm actually functions on a day-to-day basis and demonstrates the company's ability to bring in money from sales or other sources and to adequately pay salaries, taxes, and other expenses.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.
GILD Exercises Option to License Assembly Bio's Herpes Programs
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences: About To Break Out
Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results, driving optimism for continued growth. Gilead Sciences key growth drivers, include robust sales from Livdelzi and Yeztugo, alongside patent protection for Biktarvy until 2036. Despite a higher P/FCF ratio, Gilead Sciences is still undervalued, with an intrinsic value estimate of $146.12, supporting its investment case.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
